(R)-2-methylbenzo-1,4-dioxane | 1243273-39-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: (R)-2-methylbenzo-1,4-dioxane
• 英文别名: (3R)-3-methyl-2,3-dihydro-1,4-benzodioxine
• CAS: 1243273-39-3
• 化学式: C₉H₁₀O₂
• 分子量: 150.177
• InChiKey: MJCYUVOCINOVJH-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (S)-2-[(p-methoxyphenyl)(p-toluenesulfonyl)amino]propyl p-toluenesulfonate 在 caesium carbonate 、 邻苯二酚 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以48%的产率得到(R)-2-methylbenzo-1,4-dioxane
  参考文献：
  名称：

  Aryl(sulfonyl)amino Group: A Convenient and Stable Yet Activated Modification of Amino Group for Its Intramolecular Displacement

  摘要：

  Aryl(sulfonyl)amino groups, readily derived from sulfonyl- or arylamines by standard methods as well as the recently introduced methods of sulfonylation and arylation, proved to be good leaving groups in intramolecular substitution reactions by various nitrogen, oxygen, and carbon nucleophiles.

  DOI：

  10.1021/ol101541p

文献信息

• HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
  申请人：AMGEN INC.

  公开号：US20170320860A1

  公开（公告）日：2017-11-09

  Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用盐，上述任何一个的立体异构体，或它们的混合物是APJ受体的激动剂，可能用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构： 其中变量的定义在此提供。
• CXCR2 INHIBITORS
  申请人：HACHTEL Stephanie

  公开号：US20080090854A1

  公开（公告）日：2008-04-17

  The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

  该发明涉及公式I的化合物： 其中R1、R2、X、A、B、D和Y1至Y4具有声明中指示的含义，和/或其药学上可接受的盐和/或前药。由于它们作为趋化因子受体抑制剂的特性，特别是作为CXCR2抑制剂，公式I的化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。
• TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3182973B1

  公开（公告）日：2019-09-18
• SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE
  申请人：Janssen Pharmaceuticals, Inc.

  公开号：US20150141411A1

  公开（公告）日：2015-05-21

  The present invention is concerned with novel substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione derivatives of Formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
• US7220765B2
  申请人：——

  公开号：US7220765B2

  公开（公告）日：2007-05-22